Tyr402

Site Information
CsIEsDIyAEIPDEt SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 447955
Associated spectra: 2 CST

In vivo Characterization
Methods used to characterize site in vivo:	immunoassay ( 1 , 2 , 4 , 6 , 14 , 16 ) , immunoprecipitation ( 3 , 4 , 9 ) , mass spectrometry ( 18 , 19 , 21 , 22 , 23 , 24 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 37 , 38 , 41 , 42 , 43 , 44 , 45 , 47 , 51 ) , mutation of modification site ( 4 , 9 , 46 , 49 , 53 , 54 , 55 , 65 , 66 ) , phospho-antibody ( 1 , 2 , 3 , 6 , 7 , 9 , 10 , 11 , 12 , 13 , 14 , 16 , 17 , 20 , 25 , 26 , 27 , 28 , 39 , 40 , 46 , 48 , 49 , 50 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 ) , western blotting ( 3 , 4 , 6 , 7 , 9 , 10 , 11 , 12 , 13 , 14 , 16 , 17 , 20 , 25 , 26 , 27 , 28 , 39 , 40 , 49 , 50 , 52 , 53 , 54 , 61 , 62 , 63 , 64 , 65 , 66 )
Disease tissue studied:	adrenal cancer ( 16 , 53 ) , pheochromocytoma ( 16 , 53 ) , bladder cancer ( 44 ) , bone cancer ( 20 ) , breast cancer ( 2 , 9 , 12 , 66 ) , colorectal cancer ( 7 , 20 ) , colorectal carcinoma ( 7 , 20 ) , esophageal cancer ( 4 ) , esophageal carcinoma ( 4 ) , gastric carcinoma, surrounding tissue ( 32 ) , leukemia ( 18 , 19 , 27 , 38 , 41 , 42 , 43 , 45 , 47 , 49 ) , acute lymphocytic leukemia ( 43 , 45 ) , acute myelogenous leukemia ( 41 , 42 , 47 ) , chronic myelogenous leukemia ( 18 , 19 , 27 , 38 , 49 ) , lung cancer ( 17 , 21 , 22 , 23 , 26 , 52 ) , non-small cell lung cancer ( 17 , 21 , 22 , 23 , 26 ) , non-small cell lung adenocarcinoma ( 17 , 21 , 22 , 23 ) , lymphoma ( 1 , 28 ) , B cell lymphoma ( 1 ) , non-Hodgkin's lymphoma ( 1 ) , follicular lymphoma ( 1 ) , T cell lymphoma ( 28 ) , neuroblastoma ( 14 ) , multiple myeloma ( 6 ) , thymic carcinoma ( 24 ) , rheumatoid arthritis ( 39 ) , SLE ( 39 )
Relevant cell line - cell type - tissue:	'neuron, cortical'-brain ( 13 ) , 293 (epithelial) ( 10 , 53 , 66 ) , 5637 (bladder cell) ( 44 ) , A431 (epithelial) ( 57 ) , A549 (pulmonary) ( 52 ) , BAEC (endothelial) ( 61 ) , DU4475 (breast cell) ( 59 ) , H9c2 (myoblast) ( 10 ) , HCT116 (intestinal) ( 7 , 20 ) , HEK293T (epithelial) ( 9 , 13 , 54 ) , HeLa (cervical) ( 20 , 57 ) , HMVEC (endothelial) ( 55 ) , HUT-78 (T lymphocyte) ( 28 ) , HUVEC (endothelial) ( 46 , 48 , 55 ) , Jurkat (T lymphocyte) ( 28 , 29 , 30 , 31 , 33 , 34 , 35 , 37 , 51 , 60 , 65 ) , K562 (erythroid) ( 18 , 19 , 27 , 38 , 49 , 58 ) , KG-1 (myeloid) ( 56 ) , Kyse30 (esophageal) ( 4 ) , Kyse410 (esophageal) ( 4 ) , lung ( 21 , 22 , 23 ) , MCF-7 (breast cell) ( 66 ) , MDA-MB-231 (breast cell) ( 2 , 9 , 12 , 59 ) , MM.1R (B lymphocyte) ( 6 ) , MM1.S (lymphoblast) ( 6 ) , monocyte ( 3 ) , monocyte-blood ( 3 ) , mononuclear ( 39 ) , MUTZ-5 (B lymphocyte) ( 43 ) , MV4-11 (macrophage) ( 41 , 42 ) , myeloid ( 56 ) , natural killer cell-blood ( 40 ) , NCI-H1299 (pulmonary) ( 26 ) , NCI-H838 (pulmonary) ( 17 ) , neuron-'brain, hippocampus' ( 14 ) , neutrophil ( 62 ) , NK92 (natural killer cell) ( 27 ) , OCI-ly1 (B lymphocyte) ( 1 ) , OCI-ly7 (B lymphocyte) ( 1 ) , OCI/AML3 (myeloid) ( 47 ) , osteoclast ( 25 ) , P116 (T lymphocyte) ( 28 ) , PC-12 (chromaffin) ( 16 , 53 ) , RAW 264 (macrophage) ( 64 ) , SEM (B lymphocyte) ( 45 ) , SH-SY5Y (neural crest) ( 14 ) , stomach ( 32 ) , SU-DHL-4 (B lymphocyte) ( 1 ) , SYF (fibroblast) ( 53 ) , T lymphocyte ( 11 ) , T lymphocyte-blood ( 50 ) , T47D (breast cell) ( 66 ) , thymus ( 24 ) , U2OS (bone cell) ( 20 )

Upstream Regulation
Regulatory protein:	DDR1 (human) ( 7 ) , Fyn (human) ( 28 ) , HS1 (human) ( 40 ) , MYD88 (human) ( 1 ) , PSD-95 (human) ( 13 ) , RHOU (human) ( 26 ) , ZAP70 (human) ( 28 )
Putative in vivo kinases:	Pyk2 (human) ( 16 , 53 , 54 ) , Src (human) ( 49 )
Kinases, in vitro:	Src (human) ( 49 )
Treatments:	2-deoxyglucose ( 36 ) , AG17 ( 50 ) , aminoxyacetic_acid ( 10 ) , antibody ( 11 , 28 , 48 , 60 ) , BAPTA-AM ( 4 , 17 , 28 , 61 ) , Ca(2+) ( 4 ) , calcitonin ( 63 ) , calphostin_C ( 49 , 61 ) , CpG ( 1 ) , CXCL12 ( 55 , 59 ) , damnacanthal ( 28 ) , dapagliflozin ( 7 ) , depolarization ( 16 , 53 ) , dexamethasone ( 6 ) , DPI ( 61 ) , EGF ( 57 ) , EGTA ( 28 ) , ephrin_A1 ( 50 ) , fibronectin ( 40 ) , GF109203X ( 17 ) , H-89 ( 17 ) , H2O2 ( 10 , 61 ) , heregulin ( 66 ) , hyaluronan ( 25 ) , hypoxia ( 4 ) , ICAM-1 ( 11 , 40 ) , IL-15 ( 27 ) , ionomycin ( 63 ) , latrunculin_B ( 28 ) , MCP-1 ( 3 ) , mechanical stress ( 61 ) , miRNA ( 12 ) , Mn(2+) ( 49 ) , myristoylated pseudosubstrate peptide ( 3 ) , NAC ( 15 , 61 ) , NKH_477 ( 16 ) , NMDA ( 13 ) , PACAP ( 17 ) , PF-431396 ( 1 , 15 ) , phorbol_ester ( 39 , 40 , 49 , 63 ) , piceatannol ( 49 ) , PP1 ( 49 , 61 ) , PP2 ( 3 , 28 , 52 ) , PP3 ( 3 ) , proepithelin ( 62 ) , RGD ( 49 ) , siRNA ( 40 ) , sodium sulfide ( 10 ) , SU6656 ( 3 ) , TNF ( 62 ) , Trametinib ( 6 ) , U73122 ( 17 ) , vanadate ( 49 ) , VEGF ( 55 , 64 ) , VIP ( 17 ) , vitronectin ( 49 ) , wortmannin ( 28 , 49 ) , Y27632 ( 49 )

Downstream Regulation
Effects of modification on Pyk2:	enzymatic activity, induced ( 9 , 15 , 16 , 39 , 46 , 54 , 65 ) , intracellular localization ( 48 ) , molecular association, regulation ( 27 , 66 ) , phosphorylation ( 54 ) , protein degradation ( 27 ) , ubiquitination ( 27 )
Effects of modification on biological processes:	cell cycle regulation ( 55 ) , cell motility, altered ( 66 ) , cell motility, induced ( 3 ) , signaling pathway regulation ( 4 )
Induce interaction with:	HER2 (human) ( 66 ) , RASA1 (human) ( 66 ) , SOCS2 (human) ( 27 ) , Src (human) ( 66 )

Disease / Diagnostics Relevance
Relevant diseases:	breast cancer ( 66 )

References
1	Mandato E, et al. (2023) MYD88L265P augments proximal B-cell receptor signaling in large B-cell lymphomas via an interaction with DOCK8. Blood 142, 1219-1232 37467575 Curated Info
2	Twafra S, et al. (2022) A novel Pyk2-derived peptide inhibits invadopodia-mediated breast cancer metastasis. Oncogene 42 36258022 Curated Info
3	Das P, et al. (2020) A PKC¿¿-LYN-PYK2 Signaling Axis Is Critical for MCP-1-Dependent Migration and Adhesion of Monocytes. J Immunol 33277387 Curated Info
4	Chen J, et al. (2020) Membranous NOX5-derived ROS oxidizes and activates local Src to promote malignancy of tumor cells. Signal Transduct Target Ther 5, 139 32792487 Curated Info
5	Gunesch JT, et al. (2020) CD56 regulates human NK cell cytotoxicity through Pyk2. Elife 32510326 Curated Info
6	Sriskandarajah P, et al. (2020) Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS-mutant multiple myeloma. BMC Cancer 32228485 Curated Info
7	Okada J, et al. (2020) Dapagliflozin Inhibits Cell Adhesion to Collagen I and IV and Increases Ectodomain Proteolytic Cleavage of DDR1 by Increasing ADAM10 Activity. Molecules 25 31979355 Curated Info
8	Uzoma I, et al. (2018) Global Identification of Small Ubiquitin-related Modifier (SUMO) Substrates Reveals Crosstalk between SUMOylation and Phosphorylation Promotes Cell Migration. Mol Cell Proteomics 17 29438996 Curated Info
9	Genna A, et al. (2018) Pyk2 and FAK differentially regulate invadopodia formation and function in breast cancer cells. J Cell Biol 217, 375-395 29133485 Curated Info
10	Bibli SI, et al. (2017) Hydrogen Sulfide Preserves Endothelial Nitric Oxide Synthase Function by Inhibiting Proline-Rich Kinase 2: Implications for Cardiomyocyte Survival and Cardioprotection. Mol Pharmacol 92, 718-730 29030392 Curated Info
11	Eppler FJ, Quast T, Kolanus W (2017) Dynamin2 controls Rap1 activation and integrin clustering in human T lymphocyte adhesion. PLoS One 12, e0172443 28273099 Curated Info
12	Sundararajan V, et al. (2015) The ZEB1/miR-200c feedback loop regulates invasion via actin interacting proteins MYLK and TKS5. Oncotarget 6, 27083-96 26334100 Curated Info
13	Zhao C, et al. (2015) The Upregulation of NR2A-Containing N-Methyl-D-Aspartate Receptor Function by Tyrosine Phosphorylation of Postsynaptic Density 95 Via Facilitating Src/Proline-Rich Tyrosine Kinase 2 Activation. Mol Neurobiol 51, 500-11 24981431 Curated Info
14	Kinoshita Y, et al. (2014) Role for NUP62 depletion and PYK2 redistribution in dendritic retraction resulting from chronic stress. Proc Natl Acad Sci U S A 111, 16130-5 25349423 Curated Info
15	Das JK, Felty Q (2014) PCB153-Induced Overexpression of ID3 Contributes to the Development of Microvascular Lesions. PLoS One 9, e104159 25090023 Curated Info
16	Faure C, Ramos M, Girault JA (2013) Pyk2 cytonuclear localization: mechanisms and regulation by serine dephosphorylation. Cell Mol Life Sci 70, 137-52 22802128 Curated Info
17	Moody TW, Di Florio A, Jensen RT (2012) PYK-2 is Tyrosine Phosphorylated after Activation of Pituitary Adenylate Cyclase Activating Polypeptide Receptors in Lung Cancer Cells. J Mol Neurosci 48, 660-6 22581436 Curated Info
18	Mulhern D (2011) CST Curation Set: 13267; Year: 2011; Biosample/Treatment: cell line, K-562/untreated &'\|\|' untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
19	Mulhern D (2011) CST Curation Set: 13268; Year: 2011; Biosample/Treatment: cell line, K-562/untreated &'\|\|' untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
20	Malik SA, et al. (2011) BH3 mimetics activate multiple pro-autophagic pathways. Oncogene 30, 3918-29 21460857 Curated Info
21	Ren H (2011) CST Curation Set: 11772; Year: 2011; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
22	Ren H (2011) CST Curation Set: 11773; Year: 2011; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
23	Ren H (2011) CST Curation Set: 11774; Year: 2011; Biosample/Treatment: cell line, RP91/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
24	Li Y (2011) CST Curation Set: 10458; Year: 2011; Biosample/Treatment: tissue, thymus/untreated; Disease: thymic carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
25	Pivetta E, et al. (2011) Blood-derived human osteoclast resorption activity is impaired by Hyaluronan-CD44 engagement via a p38-dependent mechanism. J Cell Physiol 226, 769-79 20799279 Curated Info
26	Alan JK, et al. (2010) Regulation of the Rho family small GTPase Wrch-1/RhoU by C-terminal tyrosine phosphorylation requires Src. Mol Cell Biol 30, 4324-38 20547754 Curated Info
27	Lee SH, et al. (2010) Suppressor of cytokine signaling 2 regulates IL-15-primed human NK cell function via control of phosphorylated Pyk2. J Immunol 185, 917-28 20543098 Curated Info
28	Collins M, et al. (2010) The T cell receptor-mediated phosphorylation of Pyk2 tyrosines 402 and 580 occurs via a distinct mechanism than other receptor systems. J Leukoc Biol 87, 691-701 20028775 Curated Info
29	Possemato A (2010) CST Curation Set: 9379; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
30	Guo A (2010) CST Curation Set: 9181; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
31	Possemato A (2009) CST Curation Set: 8804; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
32	Ren H (2009) CST Curation Set: 8025; Year: 2009; Biosample/Treatment: tissue, gastrointestinal tract/untreated; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
33	Possemato A (2009) CST Curation Set: 8189; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
34	Possemato A (2009) CST Curation Set: 7996; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
35	Possemato A (2009) CST Curation Set: 7997; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
36	Zhong D, et al. (2009) The Glycolytic Inhibitor 2-Deoxyglucose Activates Multiple Prosurvival Pathways through IGF1R. J Biol Chem 284, 23225-33 19574224 Curated Info
37	Possemato A (2009) CST Curation Set: 7999; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
38	Moritz A (2009) CST Curation Set: 6446; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
39	Wang M, Sun H, Zhang W, Zhang Y (2009) Functional activation of proline-rich tyrosine kinase2 (PYK2) in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. BMC Musculoskelet Disord 10, 141 19919693 Curated Info
40	Butler B, Kastendieck DH, Cooper JA (2008) Differently phosphorylated forms of the cortactin homolog HS1 mediate distinct functions in natural killer cells. Nat Immunol 9, 887-97 18587398 Curated Info
41	Moritz A (2006) CST Curation Set: 1893; Year: 2006; Biosample/Treatment: cell line, MV4-11/Flt3 inhibitor; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
42	Moritz A (2006) CST Curation Set: 1895; Year: 2006; Biosample/Treatment: cell line, MV4-11/-; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
43	Gu T (2006) CST Curation Set: 1873; Year: 2006; Biosample/Treatment: cell line, MUTZ-5/untreated; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
44	Rikova K (2006) CST Curation Set: 1864; Year: 2006; Biosample/Treatment: cell line, 5637/serum starved; Disease: bladder cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
45	Moritz A (2006) CST Curation Set: 1822; Year: 2006; Biosample/Treatment: cell line, SEM/-; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
46	Le Boeuf F, Houle F, Sussman M, Huot J (2006) Phosphorylation of focal adhesion kinase (FAK) on Ser732 is induced by rho-dependent kinase and is essential for proline-rich tyrosine kinase-2-mediated phosphorylation of FAK on Tyr407 in response to vascular endothelial growth factor. Mol Biol Cell 17, 3508-20 16760434 Curated Info
47	Gu T (2006) CST Curation Set: 1506; Year: 2006; Biosample/Treatment: cell line, OCI/AML3/untreated; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
48	van Buul JD, et al. (2005) Proline-rich tyrosine kinase 2 (Pyk2) mediates vascular endothelial-cadherin-based cell-cell adhesion by regulating beta-catenin tyrosine phosphorylation. J Biol Chem 280, 21129-36 15778498 Curated Info
49	Butler B, Blystone SD (2005) Tyrosine phosphorylation of beta3 integrin provides a binding site for Pyk2. J Biol Chem 280, 14556-62 15695828 Curated Info
50	Aasheim HC, Delabie J, Finne EF (2005) Ephrin-A1 binding to CD4+ T lymphocytes stimulates migration and induces tyrosine phosphorylation of PYK2. Blood 105, 2869-76 15585656 Curated Info
51	Possemato A (2004) CST Curation Set: 7998; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
52	Wei L, Yang Y, Zhang X, Yu Q (2004) Altered regulation of Src upon cell detachment protects human lung adenocarcinoma cells from anoikis. Oncogene 23, 9052-61 15489898 Curated Info
53	Park SY, Avraham HK, Avraham S (2004) RAFTK/Pyk2 activation is mediated by trans-acting autophosphorylation in a Src-independent manner. J Biol Chem 279, 33315-22 15166227 Curated Info
54	Meyer AN, Gastwirt RF, Schlaepfer DD, Donoghue DJ (2004) The cytoplasmic tyrosine kinase Pyk2 as a novel effector of fibroblast growth factor receptor 3 activation. J Biol Chem 279, 28450-7 15105428 Curated Info
55	Kuwabara K, et al. (2004) Differential regulation of cell migration and proliferation through proline-rich tyrosine kinase 2 in endothelial cells. Endocrinology 145, 3324-30 15070849 Curated Info
56	Recher C, et al. (2004) Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration, increased cellularity, and poor prognosis. Cancer Res 64, 3191-7 15126359 Curated Info
57	Shi CS, Kehrl JH (2004) Pyk2 amplifies epidermal growth factor and c-Src-induced Stat3 activation. J Biol Chem 279, 17224-31 14963038 Curated Info
58	Chandhoke SK, et al. (2004) Beta 3 integrin phosphorylation is essential for Arp3 organization into leukocyte alpha V beta 3-vitronectin adhesion contacts. J Cell Sci 117, 1431-41 14996908 Curated Info
59	Fernandis AZ, et al. (2004) Regulation of CXCR4-mediated chemotaxis and chemoinvasion of breast cancer cells. Oncogene 23, 157-67 14712221 Curated Info
60	Sakakibara A, Hattori S, Nakamura S, Katagiri T (2003) A novel hematopoietic adaptor protein, Chat-H, positively regulates T cell receptor-mediated interleukin-2 production by Jurkat cells. J Biol Chem 278, 6012-7 12486027 Curated Info
61	Cheng JJ, Chao YJ, Wang DL (2002) Cyclic strain activates redox-sensitive proline-rich tyrosine kinase 2 (PYK2) in endothelial cells. J Biol Chem 277, 48152-7 12368297 Curated Info
62	Zhu J, et al. (2002) Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair. Cell 111, 867-78 12526812 Curated Info
63	Zhang Z, et al. (2002) Calcitonin induces dephosphorylation of Pyk2 and phosphorylation of focal adhesion kinase in osteoclasts. Bone 31, 359-65 12231407 Curated Info
64	Matsumoto Y, et al. (2002) Possible involvement of the vascular endothelial growth factor-Flt-1-focal adhesion kinase pathway in chemotaxis and the cell proliferation of osteoclast precursor cells in arthritic joints. J Immunol 168, 5824-31 12023386 Curated Info
65	Katagiri T, et al. (2000) Protein-tyrosine kinase Pyk2 is involved in interleukin-2 production by Jurkat T cells via its tyrosine 402. J Biol Chem 275, 19645-52 10867021 Curated Info
66	Zrihan-Licht S, et al. (2000) RAFTK/Pyk2 tyrosine kinase mediates the association of p190 RhoGAP with RasGAP and is involved in breast cancer cell invasion. Oncogene 19, 1318-28 10713673 Curated Info